Application/Control No. O9/714,692 Examiner Bridget E. Bunner Applicant(s)/Patent Under Reexamination LEE ET AL. Art Unit Page 1 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
	Α	US-				
	В	US-				
	O	US-				
	۵	US-				
	Ę	US-				
	F	US-				
	G	US-				
	н	US-				
	1	US-				
	J	US-			Ü	
	К	US-				
	L	US-				
	М	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification	
	N	2					
	0						
	Р						
	Q						
	R						
	s						
	Т						

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
1	U/	Griffioen et al. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacological Reviews 52(2): 237-268, 2000.
	6/	Perrin et al. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J. Pharmacol. Exp. Therapeutics 288: 729-734, 1999.
	W	Arbiser et al. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J. Investigative Dermatology 113(5): 838-842, 1999.
	x	Schilling et al. Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the

*A copy whis reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of R f rences Cited

Application/Control No. 09/714,692

Applicant(s)/Patent Under Reexamination LEE ET AL.

Examiner

Bridget E. Bunner

Art Unit 1647

Page 2 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
	Α	US-				
	В	US-				
	С	US-				
	D	US-				
	Ε	US-				
	F	US-				
	G	US-				
	Н	US-				
	1	US-				
	J	US-				
	κ	US-				
	L	US-				
	м	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification	
	N						
	0						
	Р						
	Q						
	R						
	S						
	Т	,					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Schoeffter et al. Functional, endogenously expresssed corticotropin-releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells. Fundam. Clin. Pharmacol. 13: 484-489, 1999.
	Υ,	Villalona-Calero et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Annals of Oncology 9: 71-77, 1998.
	W	Britton et al. Corticotropin-releasing factor (CRF) antagonist blocks activation and "anxiogenic" actions of CRF in the rat. Brain Res. 369: 303-306, 1986.
	/x	Menzaghi et al. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp.

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Therapeutics 269: 564-572, 1994.